- Report
- February 2024
- 110 Pages
Global
From €4594EUR$4,750USD£3,937GBP
- Report
- January 2024
- 200 Pages
Global
From €4013EUR$4,150USD£3,440GBP
- Report
- January 2021
- 600 Pages
United States
From €2708EUR$2,800USD£2,321GBP
- Report
- October 2022
- 80 Pages
Global
From €5754EUR$5,950USD£4,931GBP
- Report
- November 2019
- 150 Pages
Global
From €1330EUR$1,375USD£1,140GBP
€2659EUR$2,750USD£2,279GBP
- Report
- June 2019
- 679 Pages
Global
€21275EUR$22,000USD£18,234GBP
- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9671EUR$10,000USD£8,288GBP
- Report
- April 2023
- 129 Pages
Global
€4835EUR$5,000USD£4,144GBP
Lupron is a drug used in the treatment of breast cancer. It is a hormone therapy drug that works by blocking the production of estrogen, which can help slow the growth of certain types of breast cancer. It is often used in combination with other drugs, such as chemotherapy, to treat advanced stages of the disease. Lupron is also used to treat endometriosis, a condition in which tissue from the uterus grows outside of the uterus.
The Lupron market is a competitive one, with many companies offering their own versions of the drug. Lupron is available in both generic and brand-name forms, and is sold in both injectable and oral forms. It is widely available in pharmacies and online, and is covered by most insurance plans.
Companies in the Lupron market include AbbVie, Pfizer, Novartis, and Teva Pharmaceuticals. Show Less Read more
